Literature DB >> 10507319

Synthesis of [99mTc]ethylenedicysteine-colchicine for evaluation of antiangiogenic effect.

F Zareneyrizi1, D J Yang, C S Oh, S Ilgan, D F Yu, W Tansey, C W Liu, E E Kim, D A Podoloff.   

Abstract

Angiogenesis is in part responsible for tumor growth and the development of metastasis. Radiolabeled angiongenesis inhibitors would be useful to assess tumor microvasculature density. Colchicine (COL), a potent antiangiogenic agent, is known to inhibit microtubule polymerization and cell arrest at metaphase. This study aimed to develop 99mTc-labeled COL (EC-COL) using ethylenedicysteine (EC) as a chelator to assess tumor microvascular density. EC was conjugated to trimethylcolchicinic acid using N-hydroxysuccinimide and 1-ethyl-3-dimethylaminopropyl carbodiimide as coupling agents with a yield of 50-60%. In vivo stability was analyzed in rabbit serum at 0.5-4 h. Tissue distribution and planar imaging studies of [99mTc]EC-COL were evaluated in breast tumor-bearing rats at 0.5, 2 and 4 h. The data was compared to that using [99mTc]EC (control). The radiochemical yield of [99mTc]EC-COL was greater than 95%. [99mTc]EC-COL was stable in rabbit serum. In vivo biodistribution of [99mTc]EC-COL in breast tumor-bearing rats showed increased tumor-to-blood (0.52+/-0.12 to 0.72+/-0.07) and tumor-to-muscle (3.47+/-0.40 to 7.97+/-0.93) ratios as a function of time. Conversely, tumor-to-blood values showed a time-dependent decrease with [99mTc]EC over the same time period. Planar images confirmed that the tumors could be visualized clearly with [99mTc]EC-COL from 0.5 to 4 h. [99mTc]EC-COL may be useful to assess antiangiogenic and therapeutic effects during chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10507319     DOI: 10.1097/00001813-199908000-00009

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  6 in total

1.  Radiosynthesis of microtubule-targeted theranostic methyl N-[5-(3'-radiohalobenzoyl)-1H-benzimidazol-2-yl]carbamates.

Authors:  Zbigniew P Kortylewicz; Janina Baranowska-Kortylewicz
Journal:  J Labelled Comp Radiopharm       Date:  2018-04-29       Impact factor: 1.921

2.  (99m)Tc-EC-guanine: synthesis, biodistribution, and tumor imaging in animals.

Authors:  David J Yang; Kaoru Ozaki; Chang-Sok Oh; Ali Azhdarinia; Thomas Yang; Megumi Ito; Allison Greenwell; Jerry Bryant; Saady Kohanim; Vincenzo K Wong; E Edmund Kim
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

3.  Synthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes.

Authors:  Grazia Papini; Simone Alidori; Jason S Lewis; David E Reichert; Maura Pellei; Giancarlo Gioia Lobbia; Gráinne B Biddlecombe; Carolyn J Anderson; Carlo Santini
Journal:  Dalton Trans       Date:  2008-11-04       Impact factor: 4.390

4.  Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumors.

Authors:  Hiroaki Kurihara; David J Yang; Massimo Cristofanilli; William D Erwin; Dong-Fang Yu; Saady Kohanim; Richard Mendez; E Edmund Kim
Journal:  Appl Radiat Isot       Date:  2008-01-26       Impact factor: 1.513

5.  Molecular imaging of Bcr-Abl phosphokinase in a xenograft model.

Authors:  Ji Yuan Wu; David J Yang; Laura S Angelo; Saady Kohanim; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2009-03-03       Impact factor: 6.261

6.  Evaluation of a 99mTc-tricine Vascular Disrupting Agent as an In-vivo Imaging in 4T1 Mouse Breast Tumor Model.

Authors:  Mostafa Erfani; Seyed Pezhman Shirmardi; Mohammad Shafiei
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.